MCNA shoud not be part of this deal For a major pharma with the latitude to invest 4-5 years and roughly US$40M to complete a more vigorous and conclusive P3 trial, the NPV of MCNA is worth well north of US$100M, probably closer to US$200 in my opinion. That's even taking into account the risk of it not being approved. Global high margin sales are estimated at US$800M/year for bladder cancer only. I think that MCNA shouldn't be part of this questionable deal unless PLI pays for it.
--------------------
"MCNA's safety profile is superior to the other available treatments after BCG-failure (1.5% Adverse event for MNCA compared to >30% AEs for Valrubicin (Valstar)). The drug MCNA had a 100% - 250% higher efficacy in the pivotal clinical trial than Valstar (<10% DFS for Valstar, 25% DFS for MCNA) and MCNA had a 35% DFS after a one year treatment on papillary-only patients with NMIBC, which is 90% of all NMIBC cases.[9]
With MCNA there is also the unique possibility for urologists to administer the drug immediately following TURBT, as opposed to weeks after with either BCG or Mitomycyn C. This means MCNA could kill free floating cancer cells and not give them the opportunity adhere to the bladder walls, after tumors have been removed."
https://en.wikipedia.org/wiki/Telesta_Therapeutics